🔗 Share this article

An underground market for unlicensed weight-loss medications is being driven by social media fitness personalities and sellers on communication apps, according to recent findings.

Investigational Drug Gaining Traction Online

Retatrutide, which is still in research studies, is being promoted by social media influencers for its supposed fat-burning properties. Followers are urged to contact these accounts privately for source information, while also obtaining discount codes.

Thriving Commerce on Messaging Platforms

Separately, a robust market exists on messaging services, where groups with numerous of members share comparison images, injection guides and claims of next-day UK delivery. Vendors promote the substance there before directing buyers to WhatsApp for transactions.

Understanding The Experimental Drug

Retatrutide is an experimental injection created by US drugmaker Eli Lilly. The treatment targets three gut hormones – glucagon-like peptide-1, GIP and pancreatic hormone. Preliminary studies indicate it could help individuals lose up to 25% of their total weight. Nicknamed the “triple G”, the drug is being promoted online as the successor to Ozempic.

Healthcare Experts Voice Concerns

However, physicians and chemists have warned that the sale of what remains an unlicensed medication in the United Kingdom is worrisome and could lead to individuals administering substances of unknown origin.

Several professionals said the popularity for the experimental drug could be connected to the increasing cost of approved weight loss treatments such as Mounjaro.

Legal Position and Implementation

Marketing the unapproved drug on social media or Telegram is illegal in the United Kingdom, as it is an unlicensed drug that must not be promoted or supplied for personal consumption under the British medical regulations.

Several content creators try to sidestep the regulations by referring to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted substance, but promotion and supply can still violate medicines, advertising, and consumer regulations, risking penalties, prosecution or imprisonment.

Service Reaction and Material Removal

According to the social media company, the service has taken down problematic material and banned related hashtags and search suggestions. The company said it was dedicated to maintaining the service safe and allocating resources in enhancing compliance measures.

Digital Marketplace Operations

Investigations also found groups with up to 9,000 members selling retatrutide using the platform's built-in discovery tool, which operates like a online catalog. Typing “retatrutide” immediately displays channels with numerous of users, populated with images of slimming results, glowing testimonials and detailed instructions for preparing or injecting at home.

After moments of entering one community, a vendor posted WhatsApp details, where most purchases take place. The seller provided an instruction manual and guaranteed shipping within 48 hours. When questioned whether the product was genuine, one vendor responded: “You can’t be sure.” Another provided a image of a supposed laboratory certificate. Not one asked about body mass, medical conditions or previous experience.

Product Details and Pricing

Inside these communities, messages show dark colored parcels with Royal Mail labels, stating to include new batches. One message read: “It took eight of us to load them this morning.”

Customers can choose between powder vials, prepared at home with purified liquid, or pre-filled injectors typically priced at £160 for 20mg. When questioned how much time a pen should be used, vendors give conflicting responses varying between a few weeks to “depends on your body”.

Service Oversight and Safety Measures

A spokesperson for Telegram stated it actively moderated dangerous material on its service including content that promoted the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.

Medical Professional Cautions

“People are injecting materials they cannot confirm. Although the research behind retatrutide is sound, these online versions may not include what they advertise,” said Jason Murphy, the director of pharmacy at Chemist4U.

Dr Crystal Wyllie of an online medical service linked the increase in demand to current cost increases for approved weight-loss medications such as Mounjaro. “With costs increasing, patients are turning to social media. But fake treatments are highly risky. You can’t be certain what’s inside or whether the conditions they were produced in was sterile,” she explained.

Her team has previously encountered individuals harmed by self-injection from unconfirmed sources. “We understand the frustration, but buying from messaging apps or WhatsApp is taking chances with your health,” said Wyllie. “These substances could be impure or incorrectly dosed.”

Manufacturer Position

A spokesperson from Eli Lilly stated retatrutide was in third stage research studies and had not been evaluated or authorized by any government authority globally. “Consequently at this time no one can sell [it] for personal consumption,” they said, adding that any product “falsely representing itself as a company experimental product not yet approved … may expose users to possibly significant health risks”.